Primidone Tablet
Product Images NDC 42291-511

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Primidone (NDC 42291-511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

509 01

Label for Primidone Tablets, USP 50 mg oral tablets by AvKARE. The label indicates 100 tablets per bottle for prescription use only. It describes primidone as an anticonvulsant with 50 mg active ingredient per tablet and includes storage instructions as well as manufacturer information for AvKARE and Amneal Pharmaceuticals.*

FDA Label Image

511 01

Primidone Tablets, USP 250 mg oral tablet label by AvKARE. The label shows the product name, strength, and identifies it as an anticonvulsant containing 250 mg of Primidone per tablet. It includes usage instructions for dispensing in child-resistant packaging, storage conditions, and manufacturer information for AvKARE and Amneal Pharmaceuticals.*

FDA Label Image

Dosage

A dose titration schedule table for Primidone tablets, showing administration for adults and children over 8 years. The table details dosing times (AM, Noon, PM) across days 1 to 12 using 50 mg and 250 mg tablet symbols to indicate the pill strength. It guides transitioning to maintenance dosing after day 11.*

FDA Label Image

Primidone Tablets Usp 1

Chemical structure diagram of Primidone, showing its molecular formula C12H14N2O2 and molecular weight 218.25. The structure includes a phenyl ring attached to a pyrimidine ring with an ethyl group and keto and amine functional groups.*

FDA Label Image

Table 1

A data table titled 'Risk by indication for antiepileptic drugs in the pooled analysis' showing comparisons between placebo and drug patients. It includes columns for the indication, events per 1000 patients for placebo and drug patients, relative risk of drug versus placebo, and risk difference indicating additional drug patients with events per 1000 patients across indications including epilepsy, psychiatric, other, and total categories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.